Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study.
Mutations in the fibrillin-1 (FBN1) gene cause Marfan syndrome (MFS) and have been associated with a wide range of overlapping phenotypes. Clinical care is complicated by variable age at onset and the wide range of severity of aortic features. The factors that modulate phenotypical severity, both among and within families, remain to be determined. The availability of international FBN1 mutation Universal Mutation Database (UMD-FBN1) has allowed us to perform the largest collaborative study ever reported, to investigate the correlation between the FBN1 genotype and the nature and severity of the clinical phenotype. A range of qualitative and quantitative clinical parameters (skeletal, cardiovascular, ophthalmologic, skin, pulmonary, and dural) was compared for different classes of mutation (types and locations) in 1,013 probands with a pathogenic FBN1 mutation. A higher probability of ectopia lentis was found for patients with a missense mutation substituting or producing a cysteine, when compared with other missense mutations. Patients with an FBN1 premature termination codon had a more severe skeletal and skin phenotype than did patients with an inframe mutation. Mutations in exons 24-32 were associated with a more severe and complete phenotype, including younger age at diagnosis of type I fibrillinopathy and higher probability of developing ectopia lentis, ascending aortic dilatation, aortic surgery, mitral valve abnormalities, scoliosis, and shorter survival; the majority of these results were replicated even when cases of neonatal MFS were excluded. These correlations, found between different mutation types and clinical manifestations, might be explained by different underlying genetic mechanisms (dominant negative versus haploinsufficiency) and by consideration of the two main physiological functions of fibrillin-1 (structural versus mediator of TGF beta signalling). Exon 24-32 mutations define a high-risk group for cardiac manifestations associated with severe prognosis at all ages.
Faivre
L
L
Centre de Génétique, Centre Hospitalier Universitaire, Dijon, France. laurence.faivre@chu-dijon.fr
Collod-Beroud
G
G
Loeys
B L
BL
Child
A
A
Binquet
C
C
Gautier
E
E
Callewaert
B
B
Arbustini
E
E
Mayer
K
K
Arslan-Kirchner
M
M
Kiotsekoglou
A
A
Comeglio
P
P
Marziliano
N
N
Dietz
H C
HC
Halliday
D
D
Beroud
C
C
Bonithon-Kopp
C
C
Claustres
M
M
Muti
C
C
Plauchu
H
H
Robinson
P N
PN
Adès
L C
LC
Biggin
A
A
Benetts
B
B
Brett
M
M
Holman
K J
KJ
De Backer
J
J
Coucke
P
P
Francke
U
U
De Paepe
A
A
Jondeau
G
G
Boileau
C
C
D000293:Adolescent; D000328:Adult; D004815:Epidermal Growth Factor / Q000235:genetics; D005091:Exons / Q000235:genetics; D005260:Female; D000071838:Fibrillin-1; D000071837:Fibrillins; D006801:Humans; D008297:Male; D008382:Marfan Syndrome / Q000175:diagnosis*; D008840:Microfilament Proteins / Q000235:genetics*; D009154:Mutation; D010641:Phenotype; D011379:Prognosis; D017434:Protein Structure, Tertiary / Q000235:genetics; D012720:Severity of Illness Index; D016212:Transforming Growth Factor beta / Q000235:genetics; D054392:Adipokines
D004815:Epidermal Growth Factor; D000071838:Fibrillin-1; D000071837:Fibrillins; D008840:Microfilament Proteins; D016212:Transforming Growth Factor beta; C000605722:FBN1 protein, human; D054392:Adipokines
Hum Mol Genet. 1996 Oct;5(10):1581-7
8894692
IARC Sci Publ. 1987;(82):1-406
3329634
Hum Mutat. 2005 Dec;26(6):529-39
16220557
Circulation. 1996 Dec 1;94(11):2708-11
8941093
Am J Med Genet. 1996 Mar 29;62(3):233-42
8882780
J Clin Invest. 2004 Jul;114(2):172-81
15254584
J Clin Invest. 1995 May;95(5):2373-8
7738200
Am J Hum Genet. 1999 Oct;65(4):1007-20
10486319
Nat Genet. 1997 Oct;17(2):218-22
9326947
Arch Intern Med. 2001 Nov 12;161(20):2447-54
11700157
J Natl Cancer Inst. 1959 Apr;22(4):719-48
13655060
Genomics. 1993 Aug;17(2):468-75
8406497
Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10915-9
1438297
N Engl J Med. 2006 Aug 24;355(8):788-98
16928994
Semin Thorac Cardiovasc Surg. 1993 Jan;5(1):11-6
8424997
Cell. 1996 May 17;85(4):597-605
8653794
Am J Med Genet. 1996 Apr 24;62(4):417-26
8723076
Surv Ophthalmol. 2006 Nov-Dec;51(6):561-75
17134646
Nucleic Acids Res. 1987 Sep 11;15(17):7155-74
3658675
Nucleic Acids Res. 2003 Jul 1;31(13):3812-4
12824425
Hum Mutat. 2005 Nov;26(5):494
16222657
Clin Genet. 1999 Feb;55(2):110-7
10189088
Hum Mutat. 2003 Sep;22(3):199-208
12938084
J Cell Biol. 2007 Jan 29;176(3):355-67
17242066
Hum Mutat. 2005 Sep;26(3):184-91
16086365
Nat Genet. 2003 Mar;33(3):407-11
12598898
J Cell Biol. 1986 Dec;103(6 Pt 1):2499-509
3536967
Nat Genet. 2004 Aug;36(8):855-60
15235604
Hum Mol Genet. 2003 Sep 15;12(18):2269-76
12915484
Biochim Biophys Acta. 2000 Dec 20;1498(2-3):84-90
11108952
Hum Mutat. 2002 Sep;20(3):153-61
12203987
J Med Genet. 2003 Jan;40(1):34-6
12525539
Genomics. 1996 Sep 15;36(3):468-75
8884270
Am J Med Genet. 1988 Mar;29(3):581-94
3287925
Methods Enzymol. 1990;183:252-78
2314278
Nature. 1991 Jul 25;352(6333):337-9
1852208
J Med Genet. 2002 Jan;39(1):34-41
11826022
Genomics. 1994 Feb;19(3):573-6
8188302
Genome Res. 2001 May;11(5):863-74
11337480
Hum Mutat. 2002 Sep;20(3):197-208
12203992
J Clin Invest. 1995 Feb;95(2):874-80
7860770
Mol Cell Probes. 1994 Aug;8(4):325-7
7870075
Hum Mol Genet. 2003 Apr 1;12(7):727-37
12651868
Hum Mutat. 2004 Aug;24(2):140-6
15241795
Lancet. 2005 Dec 3;366(9501):1965-76
16325700
Am J Hum Genet. 2002 Aug;71(2):223-37
12068374
Hum Mol Genet. 1995;4 Spec No:1799-809
8541880
Hum Mutat. 2004 Jan;23(1):99
14695540